Video from RSNA 2022: Gadopiclenol emerges as gadolinium-based contrast agent

Nov 30, 2022
2022 12 01 19 36 6737 2022 12 01 Kuhl Video 400

CHICAGO - Gadopiclenol is emerging as an alternative gadolinium-based MRI contrast agent. To learn more about its potential, we spoke with Dr. Christiane Kuhl from the University Hospital Aachen in Germany at RSNA 2022.


Latest in Molecular Imaging
Pet Amygdala Thumbnail
PET links chronic stress to aggressive endometrial cancer
November 19, 2024
New! Imaging Life Issue 20 now available
Sponsored
New! Imaging Life Issue 20 now available
November 5, 2024
Representative maximum-intensity projections of five patients (patients 3, 5, 7, 10, and 11) comparing Ga-68 NYM046 and F-18 FDG. Both tracers showed specific retention in bone and lymph node metastases (patients 10 and 11). Ga-68 NYM046 PET/CT outperformed F-18 FDG PET/CT in detecting primary tumors, lung metastases, and pleural metastases (patients 3, 5, 7, and 11). Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of the Journal of Nuclear Medicine.
New PET tracer shows promise in patients with kidney cancer
November 14, 2024
Pluvicto Spect Ct Response Thumbnail
SPECT/CT predicts treatment response in Pluvicto patients
November 1, 2024
Related Stories
2023 07 18 20 20 0856 2023 07 18 Gadopiclinol 400 20230718200726
MRI
Gadopiclenol comparable to gadobutrol at half-dose for body MRI
2019 12 18 19 15 2524 Guerbet Rsna 2019 400
MRI
Guerbet's gadopiclenol agent classified as low risk
2022 10 03 20 54 9239 Calendar September 2022 400
MRI
New MRI contrast agent tops product news in September
New! Imaging Life Issue 20 now available
Sponsor Content
New! Imaging Life Issue 20 now available
More in Molecular Imaging
PET links chronic stress to aggressive endometrial cancer
By Will Morton
Brain activity related to chronic stress may be associated with the aggressiveness of tumors in women with endometrial cancer.
November 19, 2024
Pet Amygdala Thumbnail
FAPI-PET/CT superior to FDG-PET/CT in assessing liver cancer
By Will Morton
A recent study suggests that PET/CT imaging with a FAPI radiotracer is superior to F-18 FDG-PET/CT for assessing patients with liver cancer.
November 18, 2024
Two cases of pathologically confirmed intrahepatic cholangiocarcinomas in 68-year-old male patients. In both cases (A-H, case 1; I-P, case 2), CT scans (B, F, case 1; J, N, case 2) revealed intrahepatic bile duct dilation and suspected nodular lesions. While F-18 FDG PET/CT (A, C, D, case 1; I, K, L, case 2) failed to demonstrate abnormal tracer uptake (SUVmax 3.5, TBR 1.3 in Case 1; SUVmax 2.6, TBR 1.2 in Case 2), F-18 FAPI-04 PET/CT (E, G, H, case 1; M, O, P, case 2 ) showed positive uptake in the nodular lesions (SUVmax 9.7, TBR 3.5 in Case 1; SUVmax 9.6, TBR 3.3 in Case 2). Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of BMC Cancer.
New PET tracer shows promise in patients with kidney cancer
By Will Morton
A new PET radiotracer could offer a viable strategy for detecting primary tumors, involved lymph nodes, and distant metastases in patients with clear cell renal cell carcinoma.
November 14, 2024
Representative maximum-intensity projections of five patients (patients 3, 5, 7, 10, and 11) comparing Ga-68 NYM046 and F-18 FDG. Both tracers showed specific retention in bone and lymph node metastases (patients 10 and 11). Ga-68 NYM046 PET/CT outperformed F-18 FDG PET/CT in detecting primary tumors, lung metastases, and pleural metastases (patients 3, 5, 7, and 11). Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of the Journal of Nuclear Medicine.
SPECT/CT predicts treatment response in Pluvicto patients
By Will Morton
SPECT/CT scans taken just four hours after patients begin Lu-177 PSMA-617 treatment can help assess treatment responses.
November 1, 2024
Pluvicto Spect Ct Response Thumbnail
FCH-PET emerging in patients with hyperparathyroidism
By Will Morton
F-18 fluorocholine (FCH) PET/CT appears to be an effective first-line imaging method in patients with primary hyperparathyroidism.
October 31, 2024
Hyperparathyroidism
Ask cardiac PET patients how much they exercise, study suggests
By Will Morton
Exercise activity is an independent predictor of events such as heart attacks in patients undergoing stress PET myocardial perfusion imaging.
October 30, 2024
Heart Attack
Intraarterial PRRT safe in patients with meningioma
By Will Morton
Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma.
October 28, 2024
2024 10 28 Meningioma Thumbnail
PSMA-PET provides long-term benefits
By Will Morton
Prostate-specific membrane antigen (PSMA) PET imaging could improve the length and quality of life for patients with recurrent prostate cancer.
October 24, 2024
Prostate Imaging2
New PET tracer improves detection of insulinomas
By Will Morton
A new PET/CT radiotracer that detects insulinomas could eliminate the need for other diagnostic procedures in a vast majority of patients.
October 21, 2024
Glp 1 R Pet 67169a712e569 Thumbnail
Tc-99m shortage expected into November
By Will Morton
The delayed restart of a nuclear research reactor in the Netherlands is expected to cause supply shortages of technetium-99m (Tc-99m) into November.
October 18, 2024
Isotopes
FAPI-PET shows value in staging lung cancer patients
By Will Morton
Fibroblast activation protein inhibitor (FAPI) PET/CT shows excellent diagnostic accuracy for detecting lymph node metastases in lung cancer patients
October 17, 2024
Lung Cancer
New guidelines cover theranostics for brain tumors
By Will Morton
The use of somatostatin receptor PET imaging and therapy in meningiomas is on the rise.
October 14, 2024
Brain
Page 1 of 598
Next Page